{"id":1614,"date":"2018-11-11T20:49:35","date_gmt":"2018-11-11T19:49:35","guid":{"rendered":"http:\/\/www.newslab.sk\/2018\/11\/11\/potencial-novej-generacie-sekvenovania-pri-skriningu-lynchovho-syndromu\/"},"modified":"2018-11-11T20:53:37","modified_gmt":"2018-11-11T19:53:37","slug":"potencial-novej-generacie-sekvenovania-pri-skriningu-lynchovho-syndromu","status":"publish","type":"post","link":"https:\/\/www.newslab.sk\/en\/potencial-novej-generacie-sekvenovania-pri-skriningu-lynchovho-syndromu\/","title":{"rendered":"Potential of next generation sequencing in screening of Lynch syndrome"},"content":{"rendered":"

*All tables, charts, graphs and pictures that are featured in this article can be found in the .pdf attachment at the end of the paper.<\/span><\/strong><\/p>\n

 <\/p>\n

Lynchov syndr\u00f3m<\/strong><\/p>\n

Lynchov syndr\u00f3m (OMIM: #<\/strong>120435) (LS) je autozom\u00e1lne dominantn\u00e9 dedi\u010dn\u00e9 ochorenie sp\u00f4soben\u00e9 heterozygotn\u00fdmi z\u00e1rodo\u010dn\u00fdmi mut\u00e1ciami v g\u00e9noch mutL homolog 1 (MLH1), <\/em>mutS homolog 2 (MSH2<\/em>), <\/em>mutS homolog 6 (MSH6<\/em>) a PMS1 homolog 2 (PMS2<\/em>), <\/em>ktor\u00e9 sa podie\u013eaj\u00fa na DNA mismatch <\/em>oprav\u00e1ch (MMR; mismatch repair<\/em>). Okrem uveden\u00fdch mut\u00e1ci\u00ed v\u0161ak boli op\u00edsan\u00e9 mut\u00e1cie v g\u00e9ne pre adhez\u00edvnu molekulu epiteli\u00e1lnych buniek (EPCAM<\/em>), ktor\u00e9 sp\u00f4sobuj\u00fa epigenetick\u00fd silencing <\/em>susediaceho MMR g\u00e9nu MSH2 (graf 1)<\/strong><\/em>(1). MMR je evolu\u010dne konzervovan\u00fd proces, ktor\u00fd opravuje chyby sp\u00f4soben\u00e9 DNA polymer\u00e1zou po\u010das replik\u00e1cie gen\u00f3mu(2). Mut\u00e1cie v g\u00e9noch pre MMR sp\u00f4sobuj\u00fa poruchy mismatch <\/em>opravn\u00e9ho syst\u00e9mu, v\u00fdsledkom \u010doho je akumul\u00e1cia spont\u00e1nnych mut\u00e1ci\u00ed v DNA(3). Genetick\u00e9 anal\u00fdzy uk\u00e1zali, \u017ee u pacientov s LS je vysok\u00e1 frekvencia inzer\u010dno\/dele\u010dn\u00fdch mut\u00e1ci\u00ed, ktor\u00e9 vznikaj\u00fa v jednoduch\u00fdch sekven\u010dn\u00fdch opakovaniach (mikrosatelitoch). Obvykle sa tieto mut\u00e1cie prejavuj\u00fa ako zmeny v d\u013a\u017eke kr\u00e1tkych sekven\u010dn\u00fdch opakovan\u00ed DNA, \u010do je fenom\u00e9n zn\u00e1my tie\u017e ako mikrosatelitov\u00e1 instabilita (MSI)(4).<\/p>\n

LS sa prejavuje ako predispoz\u00edcia na r\u00f4zne typy rakoviny. Pacienti s t\u00fdmto syndr\u00f3mom maj\u00fa v\u00fdrazne zv\u00fd\u0161en\u00e9 riziko rozvoja kolorekt\u00e1lneho karcin\u00f3mu, rakoviny endometria, ale aj in\u00fdch n\u00e1dorov\u00fdch ochoren\u00ed vr\u00e1tane rakoviny \u017eal\u00fadka, vaje\u010dn\u00edkov, tenk\u00e9ho \u010dreva, mo\u010dov\u00fdch ciest a in\u00fdch (graf 2) <\/em><\/strong>(5,6). Na ozna\u010denie tohto syndr\u00f3mu sa od roku 1984 za\u010dal pou\u017e\u00edva\u0165 n\u00e1zov heredit\u00e1rny nepolyp\u00f3zny kolorekt\u00e1lny karcin\u00f3m, tento term\u00edn sa v\u0161ak pova\u017euje za nespr\u00e1vny, ke\u010f\u017ee s\u00fa\u010das\u0165ou LS m\u00f4\u017eu by\u0165 n\u00e1dory z mimo\u010drevn\u00fdch oblast\u00ed(3). LS je hlavnou pr\u00ed\u010dinou dedi\u010dnej formy kolorekt\u00e1lneho karcin\u00f3mu, ktor\u00fd patr\u00ed medzi naj\u010dastej\u0161ie pr\u00ed\u010diny \u00famrtia. Popula\u010dn\u00e9 \u00fadaje z roku 2012 uk\u00e1zali, \u017ee tento typ karcin\u00f3mu je tret\u00edm naj\u010dastej\u0161\u00edm rakovinov\u00fdm ochoren\u00edm a pr\u00e1ve slovensk\u00e1 popul\u00e1cia mu\u017eov m\u00e1 najv\u00e4\u010d\u0161iu incidenciu tohto ochorenia na svete(7).<\/p>\n

 <\/p>\n

Diagnostick\u00e9 postupy<\/strong><\/p>\n

Na identifik\u00e1ciu rod\u00edn s rizikom LS sa vyu\u017e\u00edvaj\u00fa amsterdamsk\u00e9 krit\u00e9ri\u00e1 a revidovan\u00e9 bethesdsk\u00e9 smernice, ktor\u00e9 s\u00fa zalo\u017een\u00e9 na poznatkoch o rodinnej anamn\u00e9ze a veku v \u010dase stanovenia diagn\u00f3zy(8). Pacienti, ktor\u00ed sp\u013a\u0148aj\u00fa tieto krit\u00e9ri\u00e1, s\u00fa odporu\u010den\u00ed na anal\u00fdzu MSI v n\u00e1dorovom tkanive prostredn\u00edctvom molekul\u00e1rnych met\u00f3d ako PCR a imunohistoch\u00e9mia (IHC)(9). Princ\u00edp IHC spo\u010d\u00edva v zna\u010den\u00ed MMR prote\u00ednov pomocou protil\u00e1tok. Ak je n\u00e1dorov\u00e9 tkanivo m\u00e1lo zafarben\u00e9, znamen\u00e1 to, \u017ee vo vzorke je nedostatok MMR prote\u00ednov a poukazuje to na pr\u00edtomnos\u0165 mut\u00e1cie v prisl\u00fachaj\u00facom MMR g\u00e9ne. Limit\u00e1ciou IHC met\u00f3dy s\u00fa patologick\u00e9 mut\u00e1cie, ktor\u00e9 dok\u00e1\u017eu znefunk\u010dni\u0165 k\u00f3dovan\u00fd prote\u00edn bez toho, aby ovplyvnili jeho antigenicitu. V takomto pr\u00edpade vznikne falo\u0161ne pozit\u00edvny v\u00fdsledok a pre spr\u00e1vnu interpret\u00e1ciu je potrebn\u00e1 anal\u00fdza pomocou PCR(10). Na stanovenie stup\u0148a MSI pomocou PCR sa vyu\u017e\u00edva anal\u00fdza dvoch mononukleotidov\u00fdch (BAT25, BAT26) a troch dinukleotidov\u00fdch (D2S123, D5S346, D17S250) sekven\u010dn\u00fdch opakovan\u00ed. Ak vykazuj\u00fa instabilitu dva alebo viac z t\u00fdchto markerov, n\u00e1dor sa klasifikuje ako MSI-H (High<\/em>frequency <\/em>MSI). Ak iba jeden z markerov vykazuje instabilitu,<\/p>\n

n\u00e1dor sa rad\u00ed do skupiny MSI-L (Low-frequency <\/em>MSI) a ak \u017eiadny z markerov nepreuk\u00e1\u017ee instabilitu, tumor sa pova\u017euje za stabiln\u00fd (MSS; microsatellite stable<\/em>)(11). Limit\u00e1ciou tejto met\u00f3dy s\u00fa n\u00e1dory, v ktor\u00fdch sa nenahromadil dostatok replika\u010dn\u00fdch por\u00fach na to, aby boli spo\u013eahlivo detegovate\u013en\u00e9 pro- stredn\u00edctvom PCR. V tak\u00fdch pr\u00edpadoch je potrebn\u00e1 anal\u00fdza pomocou IHC. Pribli\u017ene 10-15 % sporadick\u00fdch CRC vykazuje MSI, av\u0161ak pr\u00ed\u010dinou tejto instability s\u00fa v\u00e4\u010d\u0161inou metyl\u00e1cie v prom\u00f3tore g\u00e9nu MLH1<\/em>. Preto je potrebn\u00e1 anal\u00fdza metyl\u00e1ci\u00ed v prom\u00f3torovej oblasti g\u00e9nu MLH1<\/em>. \u010eal\u0161\u00edm testom je anal\u00fdza mut\u00e1cie p. V600E v BRAF <\/em>g\u00e9ne, preto\u017ee 50 \u2013 68 % sporadick\u00fdch tumorov, ktor\u00e9 vykazuj\u00fa MSI, obsahuje pr\u00e1ve t\u00fato mut\u00e1ciu(9). Viacer\u00e9 \u0161t\u00fadie uk\u00e1zali, \u017ee met\u00f3dy IHC a PCR je vhodn\u00e9 pou\u017e\u00edva\u0165 s\u00fa\u010dasne, napriek tomu v\u0161ak existuj\u00fa podmienky, pri ktor\u00fdch obidve met\u00f3dy poskytuj\u00fa falo\u0161ne pozit\u00edvne v\u00fdsledky, ktor\u00e9 treba overi\u0165 \u010fal\u0161\u00edmi testami(12,13,14).<\/p>\n

 <\/p>\n

Sekvenovanie novej gener\u00e1cie<\/h2>\n

S rozvojom sekvena\u010dn\u00fdch technol\u00f3gi\u00ed sa \u010doraz \u010dastej\u0161ie objavuj\u00fa \u0161t\u00fadie, ktor\u00e9 nazna\u010duj\u00fa, \u017ee pr\u00e1ve sekvenovanie novej gener\u00e1cie (NGS; next-generation sequencing<\/em>) m\u00e1 ve\u013ek\u00fd potenci\u00e1l pre skr\u00edning LS. Vhodn\u00fdm pr\u00edkladom je klinick\u00fd diagnostick\u00fd test ColoSeq. Je to test pre dedi\u010dn\u00fa formu kolorekt\u00e1lneho karcin\u00f3mu, ktor\u00fd deteguje jednonukleotidov\u00e9 z\u00e1meny, inzer\u010dn\u00e9, dele\u010dn\u00e9 a duplika\u010dn\u00e9 mut\u00e1cie v g\u00e9noch MLH1<\/em>, MSH2<\/em>, MSH6<\/em>, PMS2<\/em>, EPCAM<\/em>, APC<\/em>, MUTYH<\/em>. Pri testovan\u00ed vzoriek DNA z perif\u00e9rnej krvi onkologick\u00fdch pacientov a z bunkov\u00fdch l\u00edni\u00ed rakoviny \u010dreva t\u00e1to met\u00f3da preuk\u00e1zala 100 % senzitivitu a podarilo sa detegova\u0165 v\u0161etky typy mut\u00e1ci\u00ed vr\u00e1tane missense<\/em>, frameshift<\/em>, splicing <\/em>mut\u00e1ci\u00ed, in-frame <\/em>del\u00e9ci\u00ed, ve\u013ek\u00fdch del\u00e9ci\u00ed a duplik\u00e1ci\u00ed(15). Niektor\u00ed pacienti vykazuj\u00fa sympt\u00f3my nerozoznate\u013en\u00e9 od LS, a pritom s\u00fa nosite\u013emi patog\u00e9nnych mut\u00e1ci\u00ed v g\u00e9noch, ktor\u00e9 nie s\u00fa \u0161pecifick\u00e9 pre toto ochorenie. Prostredn\u00edctvom \u0161tandardn\u00fdch testov, ktor\u00e9 sa v s\u00fa\u010dasnosti vyu\u017e\u00edvaj\u00fa, by tieto varianty neboli identifikovan\u00e9, av\u0161ak NGS panely dok\u00e1\u017eu detegova\u0165 patog\u00e9nne varianty aj v g\u00e9noch, ktor\u00e9 nie s\u00fa \u0161pecifick\u00e9 len pre LS(16).<\/p>\n

\u0160t\u00fadia Gallego et al. sa pok\u00fasila ohodnoti\u0165 efekt\u00edvnos\u0165 NGS panelov a porovna\u0165 ich so \u0161tandardn\u00fdmi postupmi, ktor\u00e9 sa vyu\u017e\u00edvaj\u00fa pri diagn\u00f3ze dedi\u010dn\u00fdch foriem kolorekt\u00e1lneho karcin\u00f3mu a polyp\u00f3znych syndr\u00f3mov. Uk\u00e1zalo sa, \u017ee testovanie pomocou NGS panelov, ktor\u00e9 obsahuj\u00fa g\u00e9ny asociovan\u00e9 s kolorekt\u00e1lnym karcin\u00f3mom a LS, je cenovo efekt\u00edvne a odpor\u00fa\u010da sa ich pou\u017e\u00edvanie ako prv\u00fd krok na diagnostiku t\u00fdchto ochoren\u00ed(16). Predpoklad\u00e1 sa, \u017ee v bl\u00edzkej bud\u00facnosti g\u00e9nov\u00e9 panely zalo\u017een\u00e9 na NGS technol\u00f3gii zmenia pr\u00edstup skr\u00edningu LS(17). Aj t\u00e1to met\u00f3da m\u00e1 v\u0161ak svoje limit\u00e1cie. Ako sa uk\u00e1zalo v niektor\u00fdch \u0161t\u00fadi\u00e1ch, s \u010dastej\u0161\u00edm pou\u017e\u00edvan\u00edm panelov\u00e9ho testovania bude vzrasta\u0165 mno\u017estvo identifikovan\u00fdch variantov neur\u010dit\u00e9ho v\u00fdznamu(18,19). Je d\u00f4le\u017eit\u00e9, aby boli tieto varianty spr\u00e1vne anotovan\u00e9, preto je ve\u013ekou v\u00fdzvou v\u00fdvoj spo\u013eahliv\u00fdch n\u00e1strojov na ich klasifik\u00e1ciu(2).<\/p>\n

 <\/p>\n

Z\u00e1ver<\/h2>\n

\u0160tatistick\u00e9 \u00fadaje o incidencii kolorekt\u00e1lneho karcin\u00f3mu poukazuj\u00fa na potrebu v\u00fdskumu LS na Slovensku. Doposia\u013e na Slovensku nebola uroben\u00e1 \u017eiadna popula\u010dn\u00e1 \u0161t\u00fadia, ktor\u00e1 by identifikovala podiel kolorekt\u00e1lnych karcin\u00f3mov vznikaj\u00facich n\u00e1sledkom LS a neboli ani objasnen\u00e9 pr\u00ed\u010diny vysokej incidencie tohto ochorenia v slovenskej popul\u00e1cii. V tejto \u0161t\u00fadii sme pouk\u00e1zali na potenci\u00e1l NGS technol\u00f3gie, ktor\u00e1 by mohla by\u0165 efekt\u00edvnou met\u00f3dou na skr\u00edning LS pacientov, pri- \u010dom \u00fadaje z\u00edskan\u00e9 t\u00fdmto pr\u00edstupom by bolo mo\u017en\u00e9 vyu\u017ei\u0165 na vytvorenie popula\u010dn\u00fdch \u0161t\u00fadi\u00ed a n\u00e1sledn\u00e9 zodpovedanie uveden\u00fdch ot\u00e1zok.<\/p>\n

LITERAT\u00daRA<\/strong><\/p>\n

    \n
  1. Tutlewska K, <\/a>Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene as a cause of Lynch syndrome – literature Hered Can-<\/a> cer Clin Pract <\/a>2013; 11(1): 9.<\/li>\n
  2. Rasmussen LJ, <\/a>Heinen CD<\/a>, Royer-Pokora B<\/a>, et al. Pathological assessment of mismatch repair gene variants in Lynch syndrome: past, present, and Hum Mutat <\/a>2012; 33(12): 1617-1625.<\/li>\n
  3. Lynch HT<\/a>, Snyder CL, Shaw TG, et Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer 2015; 15(3): 181-194.<\/li>\n
  4. Aaltonen LA, <\/a>Peltom\u00e4ki P<\/a>, Leach FS, <\/a>et Clues to the pathogenesis of familial colorectal cancer. Science <\/a>1993; 260(5109): 812-816.<\/li>\n
  5. Leenen CH, <\/a>van Lier MG, <\/a>van Doorn HC, <\/a>et Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer \u2264 70 years. Gynecol Oncol. <\/a>2012; 125(2): 414-420.<\/li>\n
  6. Wolf AI, Buchanan AH, Farkas LM. Historical review of Lynch syndrome. J Coloproctol 2013; 33(2): 95-110.<\/li>\n
  7. https:\/\/www.wcrf.or<\/a>g<\/li>\n
  8. Lopez NE, <\/a>Peterson CY<\/a>. Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. Clin Colon Rectal Surg <\/a>2016; 29(3): 196-204.<\/li>\n
  9. Hegde M, <\/a>Ferber M, <\/a>Mao R, <\/a>et al; Working Group of the American<\/a> College of Medical Genetics and Genomics (ACMG) Laboratory Quali-<\/a> ty Assurance <\/a>ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med<\/a> 2014; 16(1): 101-116.<\/li>\n
  10. Zhang <\/a> Immunohistochemistry versus microsatellite instability testing for screening colorectal cancerpatients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing. J Mol Diagn 2008; 10(4): 301-307.<\/li>\n
  11. Boland CR, <\/a>Thibodeau SN, <\/a>Hamilton SR, <\/a>et A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determi- nation of microsatellite instability in colorectal cancer. Cancer Res 1998; 58(22): 5248-5257.<\/li>\n
  12. Overbeek LI, <\/a>Ligtenberg MJ, <\/a>Willems RW<\/a>, et Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 2008; 32(8): 1246-1251.<\/li>\n
  13. Ward RL, <\/a>Hicks S, Hawkins Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol<\/a> 2013; 31(20): 2554-2562.<\/li>\n
  14. Cragun D<\/a>, DeBate RD<\/a>, Pal T<\/a>. Applying public health screening criteria: how does universal newborn screening compare to universal tumor screening for Lynch syndrome in adults with colorectal cancer? J Genet Couns 2015; 24(3): 409-420.<\/li>\n
  15. Pritchard CC, <\/a>Smith C, <\/a>Salipante SJ, <\/a>et ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn <\/a>2012; 14(4): 357-366.<\/li>\n
  16. Gallego CJ, <\/a>Shirts BH, <\/a>Bennette CS, <\/a>et Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. J Clin Oncol <\/a>2015; 33(18): 2084-2091.<\/li>\n
  17. Peltom\u00e4ki P<\/a>. Update on Lynch syndrome Fam Cancer 2016; 15(3): 385-393.<\/li>\n
  18. Yurgelun MB<\/a>, Allen B, <\/a>Kaldate RR, <\/a>et al. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Gastroenterology <\/a>2015; 149(3): 604-13.e20.<\/li>\n
  19. Hall MJ, <\/a>Forman AD<\/a>, Pilarski R, <\/a>et <\/a> Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw 2014; 12(9): 1339-1346.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    *All tables, charts, graphs and pictures that are featured in this article can be found in the .pdf attachment at the end of the paper.   Lynchov syndr\u00f3m Lynchov syndr\u00f3m (OMIM: #120435) (LS) je autozom\u00e1lne dominantn\u00e9 dedi\u010dn\u00e9 ochorenie sp\u00f4soben\u00e9 heterozygotn\u00fdmi z\u00e1rodo\u010dn\u00fdmi mut\u00e1ciami v g\u00e9noch mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_mi_skip_tracking":false,"footnotes":""},"categories":[290],"tags":[1069,1068,374,413],"class_list":["post-1614","post","type-post","status-publish","format-standard","hentry","category-genetics","tag-colorectal-cancer","tag-lynch-syndrome","tag-next-generation-sequencing-en","tag-sekvenovanie-novej-generacie-en","typ_clanku-news"],"acf":{"abstrakt":"

    Lynch syndrome is the most common cause of hereditary colorectal carcinoma and the population of males in Slovakia have the highest incidence worldwide. Molecular methods used for examining of Lynch syndrome in current clinical practice in Slovakia have several limitations. Therefore, some patients are not always correctly diagnosed. Several studies suggest that next generation sequencing has significant potential for screening of Lynch syndrome. This method showed high sensitivity and efficiency, and its implementation into clinical practice is recommended as it should improve outcomes of patients and optimize health care system.<\/p>\n

    Keywords:<\/strong> Lynch syndrome, colorectal cancer, next generation sequencing<\/p>\n","casopis":"","strana":"125","upload_clanok":{"ID":1612,"id":1612,"title":"Potenci\u00e1l novej gener\u00e1cie sekvenovania pri skr\u00edningu Lynchovho","filename":"Potenci\u00e1l-novej-gener\u00e1cie-sekvenovania-pri-skr\u00edningu-Lynchovho.pdf","filesize":497700,"url":"https:\/\/www.newslab.sk\/wp-content\/uploads\/2018\/11\/Potenci\u00e1l-novej-gener\u00e1cie-sekvenovania-pri-skr\u00edningu-Lynchovho.pdf","link":"https:\/\/www.newslab.sk\/en\/potencial-novej-generacie-sekvenovania-pri-skriningu-lynchovho-syndromu\/potencial-novej-generacie-sekvenovania-pri-skriningu-lynchovho-2\/","alt":"","author":"7","description":"","caption":"","name":"potencial-novej-generacie-sekvenovania-pri-skriningu-lynchovho-2","status":"inherit","uploaded_to":1614,"date":"2018-11-11 19:35:15","modified":"2018-11-11 19:35:15","menu_order":0,"mime_type":"application\/pdf","type":"application","subtype":"pdf","icon":"https:\/\/www.newslab.sk\/wp-includes\/images\/media\/document.png"}},"_links":{"self":[{"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/posts\/1614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/comments?post=1614"}],"version-history":[{"count":0,"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/posts\/1614\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/media?parent=1614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/categories?post=1614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newslab.sk\/en\/wp-json\/wp\/v2\/tags?post=1614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}